Agenus Inc. is a biotechnology company focused on developing immuno-oncology therapies for cancer treatment. Its proprietary platform includes a range of monoclonal antibodies and adjuvants, with key assets in the U.S. and Europe targeting various cancer types, particularly through its lead product, AGEN2034, an anti-PD-1 antibody.
Business Overview
Agenus generates revenue primarily through the commercialization of its immuno-oncology products, leveraging its proprietary technology and partnerships for research and development. The company has a competitive advantage through its innovative approach to immune modulation and a strong pipeline of clinical candidates.
Clinical trial results for AGEN2034 and other pipeline candidates
Partnership announcements or collaborations with larger pharmaceutical companies
Regulatory approvals or setbacks for key products
Market adoption rates of its therapies in oncology
Risk Factors
Regulatory changes impacting drug approval processes
Technological disruption in immunotherapy approaches
Intense competition from other biotech firms developing similar immuno-oncology therapies
Potential for larger pharmaceutical companies to out-innovate or acquire key technologies
Negative cash flow and reliance on external funding to support R&D
High operational costs with limited revenue generation
Macro Sensitivity
low - the demand for cancer therapies is relatively inelastic, as patients require treatment regardless of economic conditions.
Moderate - rising interest rates could increase the cost of capital, affecting funding for ongoing clinical trials and R&D activities.
minimal - the company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
Profile
growth - investors are likely attracted to the potential for significant upside from successful drug development.
high - the stock has shown significant price fluctuations, indicative of the high-risk nature of biotech investments.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
